Why some breast cancer becomes resistant to hormone therapy
An unexpected finding in women with estrogen receptor-positive metastatic breast cancer is the emergence of acquired mutations in HER2. These mutations explain some of the resistance to hormone-directed therapy that is seen in these patients, and the new finding could offer a new approach to clinical management, researchers said at a media preview for the American Association for Cancer Research 2018 Annual Meeting.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063